Ivo Timmermans

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.